Surveillance of Colorectal Dysplasia to Treat Inflammatory Bowel Disease with Wide Area Transepithelial Sample (WATS)


About this study

The purpose of this study is to determine if WATS 3D (The Wide Area Transepithelial Sample with three dimension analysis) can be used to adequately sample the colon and identify dysplasia in patients with Irritable Bowel Disease (IBD) undergoing surveillance. 


Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Both males and females will be enrolled and must be at least 18 years of age.
  • Patients with a known history of IBD and dysplasia (low grade or high grade) undergoing surveillance.
  • Only patients who undergo both WATS and standard biopsy will be included in this study.
  • Institutional Review Board (IRB)-approved consent must be signed by patients to participate in this study.

Exclusion Criteria:

  • Individuals < 18 years of age.

Eligibility last updated 2/7/22. Questions regarding updates should be directed to the study team contact.


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Nayantara Coelho-Prabhu, M.B.B.S.

Open for enrollment

Contact information:

Priscila Santiago Liberato de Mattos M.D.

More information


Publications are currently not available

Mayo Clinic Footer